These markers include Human Epidermal Growth Factor Receptor 2 (HER-2), estrogen receptors (ERs), and progesterone receptors (PRs), which serve as therapeutic targets for breast cancer drugs and indicators for selecting effective treatment strategies. This evidence concerns the gene ERBB2 and breast carcinoma.